Skip to Content

Aclaris Therapeutics Inc ACRS

Morningstar Rating
$0.90 +0.03 (3.30%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACRS is trading at a 60% discount.
Price
$0.87
Fair Value
$9.52
Uncertainty
Extreme
1-Star Price
$36.17
5-Star Price
$7.69
Economic Moat
Rqnq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACRS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.87
Day Range
$0.840.93
52-Week Range
$0.5918.54
Bid/Ask
$0.88 / $0.91
Market Cap
$64.01 Mil
Volume/Avg
3.5 Mil / 3.8 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.81
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Small Core
Total Number of Employees
105

Valuation

Metric
ACRS
Price/Earnings (Normalized)
Price/Book Value
0.40
Price/Sales
2.81
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ACRS
Quick Ratio
3.78
Current Ratio
4.50
Interest Coverage
Quick Ratio
ACRS

Profitability

Metric
ACRS
Return on Assets (Normalized)
−34.30%
Return on Equity (Normalized)
−44.46%
Return on Invested Capital (Normalized)
−44.32%
Return on Assets
ACRS

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncMbk$191.5 Bil
DHR
Danaher CorpNczfxs$165.0 Bil
IQV
IQVIA Holdings IncJhrrnc$39.1 Bil
IDXX
IDEXX Laboratories IncPjrwgn$38.7 Bil
A
Agilent Technologies IncSdtd$37.3 Bil
MTD
Mettler-Toledo International IncXwrntx$23.7 Bil
ICLR
Icon PLCKdysl$22.0 Bil
LH
Laboratory Corp of America HoldingsHzccbcd$18.4 Bil
WAT
Waters CorpTvgj$16.6 Bil
ILMN
Illumina IncBtwhg$16.2 Bil